Not exact matches
Different classes of MHC molecules exist and are involved in
immunity against pathogens and
tumor cells as well as the formation of immune tolerance to self - antigens.
Immunity is key to long - term responses Knowing that the immune system is capable of recognizing distinctive features of cancer cells and launching a T cell attack
against those
tumor antigens, and that checkpoint blockade removes a roadblock to that attack, it's logical that these drugs should work
against many
tumor types.
James P. Allison and Matthew Krummel demonstrate that a monoclonal antibody directed
against the CTLA - 4 molecule in a mouse model of melanoma could result in the rejection of
tumors and that this rejection also resulted in
immunity to a second exposure to
tumor cells.
It is known that macrophages are an important component of the innate
immunity against tumors and they are attracted by locally secreted chemokines [4].
While much recent research has not been published in this area, there is actually a long history of studies that show: (1) there is a significant number of antigens shared between
tumors and embryonic tissues (called «oncofetal antigens») and, consequently, antibodies made
against tumors can also recognize embryonic tissues, and vice versa; (2) pregnancy confers some
immunity against cancer (accompanied by antibody production
against oncofetal antigens), not only
against its occurrence but also
against its growth; (3) similar to pregnancy, an immune response
against cancer can be generated by vaccinating animals with embryonic tissues.
Malignant
tumors corrupt such immunosuppressive principles to protect themselves
against anti-tumor
immunity.